JP2013505201A5 - - Google Patents

Download PDF

Info

Publication number
JP2013505201A5
JP2013505201A5 JP2012503432A JP2012503432A JP2013505201A5 JP 2013505201 A5 JP2013505201 A5 JP 2013505201A5 JP 2012503432 A JP2012503432 A JP 2012503432A JP 2012503432 A JP2012503432 A JP 2012503432A JP 2013505201 A5 JP2013505201 A5 JP 2013505201A5
Authority
JP
Japan
Prior art keywords
formulation
ligand
trl9
conjugate
liposome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012503432A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013505201A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/001017 external-priority patent/WO2010114628A2/en
Publication of JP2013505201A publication Critical patent/JP2013505201A/ja
Publication of JP2013505201A5 publication Critical patent/JP2013505201A5/ja
Pending legal-status Critical Current

Links

Images

JP2012503432A 2009-04-03 2010-04-05 広域反応性中和抗ｈｉｖ抗体を誘導するための配合物 Pending JP2013505201A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16662509P 2009-04-03 2009-04-03
US61/166,625 2009-04-03
PCT/US2010/001017 WO2010114628A2 (en) 2009-04-03 2010-04-05 Formulation for inducing broadly reactive neutralizing anti-hiv antibodies

Publications (2)

Publication Number Publication Date
JP2013505201A JP2013505201A (ja) 2013-02-14
JP2013505201A5 true JP2013505201A5 (https=) 2013-11-21

Family

ID=42828908

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012503432A Pending JP2013505201A (ja) 2009-04-03 2010-04-05 広域反応性中和抗ｈｉｖ抗体を誘導するための配合物

Country Status (6)

Country Link
US (1) US9402917B2 (https=)
EP (1) EP2413951A4 (https=)
JP (1) JP2013505201A (https=)
AU (1) AU2010232915A1 (https=)
CA (1) CA2757240A1 (https=)
WO (1) WO2010114628A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200726479A (en) 2005-04-12 2007-07-16 Univ Duke Method of inducing neutralizing antibodies to human immunodeficiency virus
EP2139516A4 (en) * 2007-04-13 2011-06-29 Univ Duke METHOD FOR INDUCING NEUTRALIZING ANTIBODY AGAINST HIV
US20120070488A1 (en) * 2007-09-28 2012-03-22 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
US20140322262A1 (en) * 2007-09-28 2014-10-30 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
CA2757240A1 (en) 2009-04-03 2010-10-07 Duke University Formulation for inducing broadly reactive neutralizing anti-hiv antibodies
WO2011106100A2 (en) * 2010-02-25 2011-09-01 Duke University Method of inducing the production of protective anti-hiv-1 antibodies
US20140093556A1 (en) * 2011-01-28 2014-04-03 Sanofi Pasteur Sa Immunological Compositions Against HIV
WO2014020205A2 (es) * 2012-07-31 2014-02-06 Universidad De Granada Inmunógenos anti-vih mejorados
CA2889064A1 (en) 2012-10-19 2014-04-24 The Council Of The Queensland Institute Of Medical Research Improved human herpesvirus immunotherapy
US10076567B2 (en) * 2013-09-27 2018-09-18 Duke University MPER-liposome conjugates and uses thereof
WO2024097957A1 (en) * 2022-11-03 2024-05-10 Duke University Novel antibodies for hiv and methods of making and using the same

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020141A1 (en) 1993-03-11 1994-09-15 The University Of Southern California Therapeutic strategies for immunoinfective cluster virus infections
ES2204919T3 (es) 1993-05-27 2004-05-01 Entremed, Inc. Composiciones y procedimientos de tratamiento del cancer y de enfermedades hiperproliferativas.
JPH10504798A (ja) 1994-03-14 1998-05-12 ユニバーシティー オブ サウザーン カリフォルニア Ｈｉｖ−１感染の診断方法および処置方法
US6156337A (en) 1994-07-08 2000-12-05 Opperbas Holding B.V. Method for high loading of vesicles with biopolymeric substances
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1250933A1 (en) 2001-04-17 2002-10-23 Istituto Superiore di Sanità Vaccines including as an adjuvant high dose type I IFN
AU2003300184B8 (en) * 2002-12-30 2009-12-03 3M Innovative Properties Company Immunostimulatory combinations
EP1613643A4 (en) 2003-03-27 2009-10-28 Sudhir Paul LUPUS ANTIBODIES FOR THE PASSIVE IMMUNE THERAPY OF HIV / AIDS
US20080057075A1 (en) 2005-04-12 2008-03-06 Haynes Barton F Method of inducing neutralizing antibodies to human immunodeficiency virus
TW200726479A (en) 2005-04-12 2007-07-16 Univ Duke Method of inducing neutralizing antibodies to human immunodeficiency virus
EP2139516A4 (en) * 2007-04-13 2011-06-29 Univ Duke METHOD FOR INDUCING NEUTRALIZING ANTIBODY AGAINST HIV
BRPI0811228A2 (pt) * 2007-05-24 2014-10-21 Glaxonsmithkline Biolog S A Composição liofilizada, e, métodos para produzir uma composição liofilizada e para produzir uma composição imunológica.
US20120070488A1 (en) 2007-09-28 2012-03-22 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
US20140322262A1 (en) 2007-09-28 2014-10-30 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
WO2009111304A2 (en) 2008-02-29 2009-09-11 President And Fellows Of Harvard College A fusion-intermediate state of hiv-1 gp41 targeted by broadly neutralizing antibodies
SMT202000101T1 (it) 2008-10-10 2020-03-13 Childrens Medical Center Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente
WO2010045613A1 (en) 2008-10-16 2010-04-22 New York Blood Center Immunoenhancer-linked oligomeric hiv vaccines
AU2010232916A1 (en) 2009-04-03 2011-10-27 Children's Medical Center Corporation Formulation
CA2757240A1 (en) 2009-04-03 2010-10-07 Duke University Formulation for inducing broadly reactive neutralizing anti-hiv antibodies

Similar Documents

Publication Publication Date Title
JP2013505201A5 (https=)
Azmi et al. Recent progress in adjuvant discovery for peptide-based subunit vaccines
RU2014136401A (ru) Композиции neisseria meningitidis и способы их применения
JP2009510133A5 (https=)
WO2007095976A3 (de) Adjuvanz in form einer lipid-modifizierten nukleinsäure
EP3281956A3 (en) Human antibody drug conjugates against tissue factor
WO2007099446A3 (en) Virosome-like vesicles comprising gp41-derived antigens
EP2269639A3 (en) Influenza vaccine formulations for intradermal delivery
RU2014141545A (ru) Нацеливающие аминокислотные липиды
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
JP2012522802A5 (https=)
WO2012051211A3 (en) Antigen delivery platforms
WO2009095226A3 (en) NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS
HRP20170433T1 (hr) Pripravci spoja za izmjenu lipidiranog imunološkog odgovora, formulacije, i postupci
JP2012521201A5 (https=)
CA2523032A1 (en) Vaccines for cancer therapy
RU2017129340A (ru) Композиции nеisseria мeningitidis и способы их получения
WO2010114628A3 (en) Formulation for inducing broadly reactive neutralizing anti-hiv antibodies
MX341775B (es) Vectores para vacunas y metodos para potenciar respuestas inmunes.
JP2008539252A5 (https=)
WO2011000962A3 (en) Hiv related peptides combination or fusion for use in hiv vaccine composition or as diagnostic means
Serrano et al. Structure and immunogenicity of a peptide vaccine, including the complete HIV-1 gp41 2F5 epitope: implications for antibody recognition mechanism and immunogen design
JP2015504897A5 (https=)
WO2013082535A3 (en) Controlled-release peptide compositions and uses thereof
JP2010523676A5 (https=)